Home › Funds › Commodore Capital LP › AMLX
Commodore Capital LP position in AMLX
AMYLYX PHARMACEUTICALS INC · Health Care
Commodore Capital LP reported holding 5,650,000 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$101.5M, representing 6.04% of its reported portfolio and ranking #5 among its reported holdings. Commodore Capital LP has disclosed AMLX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Commodore Capital LP's AMLX position evolved
Commodore Capital LP first disclosed a stake in AMLX in Q3 2025 at 4,075,478 shares (US$55.4M). The position peaked in Q2 2026 at 5,650,000 shares, worth US$101.5M. Across 4 filings, Commodore Capital LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 5,650,000 shares valued at US$101.5M. Notable position changes include a 39% increase in Q4 2025 (shares rose 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 4.08M | $55.39M | New |
| Q4 2025 | 5.65M | $68.25M | Add |
| Q1 2026 | 5.65M | $78.53M | Hold |
| Q2 2026 | 5.65M | $101.47M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AMLX and 13F data
AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 50 other funds we track also report a position in AMLX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$149.7M), TCG Crossover Management, LLC (US$112.1M), Saturn V Capital Management LP (US$83.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AMLX
- PERCEPTIVE ADVISORS LLC 8.33M sh · $149.69M · Q2 2026
- TCG Crossover Management, LLC 6.24M sh · $112.14M · Q2 2026
- Saturn V Capital Management LP 4.62M sh · $83.05M · Q2 2026
- First Light Asset Management, LLC 3.02M sh · $54.30M · Q2 2026
- Siren, L.L.C. 1.48M sh · $26.59M · Q2 2026
- Almitas Capital LLC 974.88K sh · $17.51M · Q2 2026
- Jones Hill Capital LP 894.06K sh · $16.06M · Q2 2026
- Boxer Capital Management, LLC 800.00K sh · $14.37M · Q2 2026
- GREAT POINT PARTNERS LLC 700.00K sh · $12.57M · Q2 2026
- Parkman Healthcare Partners LLC 398.78K sh · $7.16M · Q2 2026
- HighVista Strategies LLC 386.08K sh · $6.93M · Q2 2026
- STEMPOINT CAPITAL LP 384.30K sh · $6.90M · Q2 2026
More on Commodore Capital LP
FAQ
How long has Commodore Capital LP held AMLX?
Commodore Capital LP has disclosed AMLX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Commodore Capital LP's current position in AMLX?
As of Q2 2026, Commodore Capital LP holds 5.65M shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $101.47M, representing 6.04% of its reported portfolio and ranking #5.
Has Commodore Capital LP been buying or selling AMLX?
In the latest 13F filing (Q2 2026), Commodore Capital LP held unchanged its position in AMLX. The position peaked in Q2 2026 at 5.65M shares.
Which other funds hold AMLX?
Other major institutional holders of AMLX include PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, Saturn V Capital Management LP, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.